Downloads
Abstract
Introduction: Actually, diagnosis for ALK gene rearrangement has been used by IHC staining technique with the D5F3 Ventana specific antibody. In addition to other diagnostic techniques such as FISH staining, next generation sequencing. The technique of ALK with IHC staining has been recognized and widely used in the world.
Methods: A retrospective and descriptive statistics research on 96 cases of lung cancer adenocarcinoma with negative EGFR mutation which have been performed diagnosis ALK rearrangment by immunohisto- chemistry with D5F3 Ventana antibody and compared to the ALK diagnosis by next generation sequencing.
Results: ALK detection rate: 7.29%; Sensitivity: 87.5%; Specificity: 100%, Positive Predictive Value: 100%, Negative Predictive Value: 98.87% and Overall Value: 98.96%.
Conclusion: Our research results demonstrate the high value of IHC with the D5F3 Ventana specific antibody in ALK rearrangement diagnosis. This technique has also been recognized around the world and this research result can also be widely used at pathology laboratory in Vietnam.
References
Alice T. Shaw et al ; ALK in Lung Cancer: Past, Present, and Future; JOURNAL OF CLINICAL ONCOLOGY, VOLUME 31, NUMBER 8, MARCH 10 2013, p1105-1117.
Antonio M. , Alessia D. L. et al ; ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm; Journal of Thoracic Oncology Vol. 11 No. 4: p487-495.
Christina I Selinger et al; Testing for ALK rearrangement in lung adenocarcinoma: a multi- center comparison of immunohistochemistry and fluorescent in situ hybridization; ASCP 2013, Modern Pathology (2013) 26, p1545– 1553.
Cristina Teixidó et al; Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements; Translational Lung Cancer Research 2014;3(2):p70-74.
David G. Beer et.al.; ALK and Other Gene Fusions in Lung Cancer; ASCP, Diagnosis & Therapy on Lung Cancer, Ver.3-2017, p15-20.
Eunhee S. Y. et al ; Correlation of IHC and FISH for ALK Gene Rearrangement in Non- small Cell Lung Carcinoma - IHC Score Algorithm for FISH; Journal of Thoracic Oncology, Volume 6, Number 3, March 2011, p459-466.
Eugen C. M. et al ; ALK Status Testing in Non Small Cell Lung Carcinoma - Correlation Between Ultrasensitive IHC and FISH; 2013 American Society for Investigative Pathology and the Association for Molecular Pathology, 8, p234-256.
Greta A. et al; ALK Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers - Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment; Arch Pathol Lab Med - Vol 138, November 2014, p1449- 1462.
Hyojin K. et al; Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group; 2014 The Korean Society of Pathologists/The Korean Society for Cytopathology; Vol.5, 2014, p1-19.
Johanna S. M. M. et al ; Inconsistent results in the analysis of ALK rearrangements in non- small cell lung Cancer; BMC Cancer (2016) 16:603, p 01-15.
Jung-S. P. et al ; ALK immunohistochemistry for ALK gene rearrangement screening in non- small cell lung cancer: a systematic review and meta-analysis; 2016 Wichtg Publishing, Role of ALK IHC in NSCLC, p414-423.
J. Ying et al ; Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma; Annals of Oncology 24: 2589– 2593, 2013.
Leilei Liu et al; Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods; National Natural Science Foundation of China, March 18, 2015, Vol.15, 01-09.
LynetteM.S.etal;Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas; Journal of Thoracic Oncology, Volume 8, Number 3, March 2013, p322-328.
Maximilian V. L et al; Multicenter Immunohistochemical ALK-Testing of NSCLC Shows High Concordance after Harmonization of Techniques and Interpretation Criteria; Journal of Thoracic Oncology, Volume 9, Number 11, November 2014, p1685–1692.
Neal I. L. et al ; Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors - Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology; Journal of Thoracic Oncology 2018, Vol. 13 No. 3: p 323-358.
Paul Hofman et.al.; ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice; Cancers 2017, 9, p.107-119.
Rathi N. P. et al; Advances in the Diagnosis and Treatment of Non–Small Cell Lung Cancer; 2014 American Association for Cancer Research; Molecular Cancer Therapies, p.556-561.
Soda M, et al.; A Guide to Lung Cancer Testing ALK & ROS1; Pfizer Oncology; 2013 Edition 2, p.23-27.
Spasenija S. et al; Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens; Journal of Thoracic Oncology, Volume 8, Number 8, August 2013, p.1004-1011.
Weiya W. et al; Detection of ALK Rearrangements in Malignant Pleural Effusion Cell Blocks From Patients With Advanced Non- Small Cell Lung Cancer: A Comparison of Ventana Immunohistochemistry and Fluorescence In Situ Hybridization; Cancer (Cancer Cytopathol) 2015;123:117-22. 2014 American Cancer Society.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital